Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949562 | 0.85 | TDP1 (0.50) | TDP1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL18201 | 0.83 | TDP1 (0.57) | TDP1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL8427582 | 0.83 | TDP1 (0.49) | TDP1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL30592857 | 0.83 | TDP1 (0.57) | TDP1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL31081770 | 0.83 | TDP1 (0.49) | TDP1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL29980732 | 0.81 | RAB9A (0.58) | TDP1MAPTGAASMN1; SMN2HPGD | |
| SCHEMBL2488525 | 0.81 | TDP1 (0.47) | TDP1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL6609846 | 0.81 | TDP1 (0.47) | TDP1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL1723847 | 0.81 | RAB9A (0.58) | TDP1MAPTGAASMN1; SMN2HPGD | |
| SCHEMBL311206 | 0.81 | TDP1 (0.69) | TDP1MAPTGAASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105246896-B | The ketone derivatives of pyrazoles pyrrolizine 4 and its purposes in treatment disease | 诺华股份有限公司 | 2017-09-08 | — | — | CN | disclosed |
| US-7423168-B2 | Reacting allyl starting compound with oxygen nucleophilic agent in presence of transition metal catalyst and monodentate phosphite | MITSUBISHI CHEMICAL CORPORATION (JP) | 2008-09-09 | — | — | US | disclosed |
| US-7241857-B2 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7173157-B2 | Method for producing an allyl compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7119222-B2 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-10-10 | — | — | US | disclosed |
| US-20060106181-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-05-18 | — | — | US | disclosed |
| US-20050075518-A1 | Method for producing allyl compound, and allyl compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-04-07 | — | — | US | disclosed |
| US-20040147757-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040092777-A1 | Method for producing allyl compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106181-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | AGPAT5, TST, AGPAT2 | TDP1 4654/4885MAPT 2696/4885GAA 2275/4885 |
| US-20040147757-A1 | Method for producing allyl compound, and ether or ester compound produced thereby | AGPAT5, TST, AGPAT2 | TDP1 4654/4885MAPT 2696/4885GAA 2275/4885 |
| US-20040092777-A1 | Method for producing allyl compound | CCNT1, APEX1, REV1 | TDP1 3793/4885MAPT 3604/4885GAA 4745/4885 |
| US-20050075518-A1 | Method for producing allyl compound, and allyl compound produced thereby | CCNT1, AOC3, ATL3 | TDP1 4503/4885MAPT 3247/4885GAA 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.